Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

被引：2
|
作者：
Ishido, Shun [1 ]
Tamaki, Nobuharu [1 ]
Inada, Kento [1 ]
Itakura, Jun [1 ]
Takahashi, Yuka [1 ]
Uchihara, Naoki [1 ]
Suzuki, Keito [1 ]
Tanaka, Yuki [1 ]
Miyamoto, Haruka [1 ]
Yamada, Michiko [1 ]
Matsumoto, Hiroaki [1 ]
Nobusawa, Tsubasa [1 ]
Keitoku, Taisei [1 ]
Takaura, Kenta [1 ]
Tanaka, Shohei [1 ]
Maeyashiki, Chiaki [1 ]
Yasui, Yutaka [1 ]
Tsuchiya, Kaoru [1 ]
Nakanishi, Hiroyuki [1 ]
Kurosaki, Masayuki [1 ,2 ]
Izumi, Namiki [1 ]
机构：
[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan
[2] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan
来源：
CLINICAL CASE REPORTS | 2023年 / 11卷 / 07期
关键词：
comprehensive genomic profiling; fibroblast growth factor receptor 2; intrahepatic cholangiocarcinoma; pemigatinib; PHASE-II; MULTICENTER; GEMCITABINE; CISPLATIN; S-1;
D O I：
10.1002/ccr3.7664
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Key Clinical MessageThe liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Oncogenic RAS Drives Resistance to Pemigatinib in Cholangiocarcinoma Harboring a FGFR2 Delins Disrupting Ligand Binding
    Lim, Mir
    Lynch, Patrick T.
    Bai, Xiaochen
    Hsiehchen, David
    JCO PRECISION ONCOLOGY, 2023, 7
  • [42] Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Vu, Phuong
    Deshpande, Vikram
    Kambadakone, Avinash
    Mussolin, Benedetta
    Reyes, Stephanie
    Henderson, Laura
    Sun, Jiaoyuan Elisabeth
    Van Seventer, Emily E.
    Gurski, Joseph M., Jr.
    Baltschukat, Sabrina
    Schacher-Engstler, Barbara
    Barys, Louise
    Stamm, Christelle
    Furet, Pascal
    Ryan, David P.
    Stone, James R.
    Iafrate, A. John
    Getz, Gad
    Porta, Diana Graus
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER DISCOVERY, 2017, 7 (03) : 252 - 263
  • [43] Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients
    Goyal, Lipika
    Saha, Supriya K.
    Liu, Leah Y.
    Siravegna, Giulia
    Leshchiner, Ignaty
    Ahronian, Leanne G.
    Lennerz, Jochen K.
    Phuong Vu
    Mussolin, Benedetta
    Reyes, Stephanie
    Furet, Pascal
    Iafrate, A. John
    Getz, Gad
    Porta, Diana G.
    Tiedt, Ralph
    Bardelli, Alberto
    Juric, Dejan
    Corcoran, Ryan B.
    Bardeesy, Nabeel
    Zhu, Andrew X.
    CANCER RESEARCH, 2017, 77
  • [44] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Giovanni Brandi
    Valeria Relli
    Marzia Deserti
    Andrea Palloni
    Valentina Indio
    Annalisa Astolfi
    Salvatore Serravalle
    Alessandro Mattiaccio
    Francesco Vasuri
    Deborah Malvi
    Chiara Deiana
    Maria Abbondanza Pantaleo
    Matteo Cescon
    Alessandro Rizzo
    Masaru Katoh
    Simona Tavolari
    Scientific Reports, 14
  • [45] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Brandi, Giovanni
    Relli, Valeria
    Deserti, Marzia
    Palloni, Andrea
    Indio, Valentina
    Astolfi, Annalisa
    Serravalle, Salvatore
    Mattiaccio, Alessandro
    Vasuri, Francesco
    Malvi, Deborah
    Deiana, Chiara
    Pantaleo, Maria Abbondanza
    Cescon, Matteo
    Rizzo, Alessandro
    Katoh, Masaru
    Tavolari, Simona
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [46] COST-EFFECTIVENESS OF PEMIGATINIB FOR PATIENTS WITH ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA AND FGFR2 FUSIONS/ REARRANGEMENTS: 2024 FIGHT-202 TRIAL FINAL RESULTS
    Huang, W. M.
    Wang, I. T.
    Chen, H. L.
    Chueh, C. H.
    Chiang, N. J.
    Tsai, Y. W.
    VALUE IN HEALTH, 2024, 27 (12)
  • [47] Prolonged Clinical Benefit with Futibatinib in a Patient with FGFR Inhibitor-Pretreated FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma: Case Report
    d'Arienzo, Paolo D.
    MacDonald, Alan R.
    Patel, Virjen
    Ma, Yuk T.
    Pihlak, Rille
    Starling, Naureen
    ONCOTARGETS AND THERAPY, 2024, 17 : 489 - 496
  • [48] A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma
    Chu, Zhenzhen
    Zhang, Baohuan
    Zhou, Xuxuan
    Yuan, Hui
    Gao, Chongqing
    Liu, Lihao
    Xiao, Yang
    Zhang, Jichun
    Hong, Jian
    Liang, Junjie
    Chen, Dong
    Yao, Nan
    MOLECULAR THERAPY NUCLEIC ACIDS, 2023, 34
  • [49] Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
    Daniela Sia
    Bojan Losic
    Agrin Moeini
    Laia Cabellos
    Ke Hao
    Kate Revill
    Dennis Bonal
    Oriana Miltiadous
    Zhongyang Zhang
    Yujin Hoshida
    Helena Cornella
    Mireia Castillo-Martin
    Roser Pinyol
    Yumi Kasai
    Sasan Roayaie
    Swan N. Thung
    Josep Fuster
    Myron E. Schwartz
    Samuel Waxman
    Carlos Cordon-Cardo
    Eric Schadt
    Vincenzo Mazzaferro
    Josep M. Llovet
    Nature Communications, 6
  • [50] FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)
    Almquist, D. R.
    Javle, M.
    Ciombor, K. K.
    Roth, M.
    Abdel-Wahab, R.
    Ou, F-S.
    Wolfe, E.
    Mody, K.
    Mahipal, A.
    Borad, M. J.
    Bekaii-Saab, T.
    Ahn, D.
    ANNALS OF ONCOLOGY, 2019, 30
12345